Donald Trump announced a massive tariff plan last week that would have upended the global economic order as well as long-established trading relationships with America's allies.

But that plan - or at least a significant part of is - is on ice after the president suspended higher tariffs on most countries for 90 days while leaning into a trade war with China.

So with this partial reversal, is Trump any closer to realising his goals on trade? Here's a quick look at five of his key ambitions and where they now stand.

1) Better trade deals

What Trump said: For decades, our country has been looted, pillaged, and plundered by nations near and far, both friend and foe alike

Trump's original trade plan packed a big punch that landed around the world, with a flat 10% baseline tariff on everyone (including some uninhabited islands) and additional "reciprocal" tariffs on the 60 counties that he said were the worst offenders.

It sent allies and adversaries scrambling, as they stared down the prospect of a debilitating blow to their economies.

The White House has been quick to boast about all the world leaders who have reached out to the president to make deals and offer trade concessions – "more than 75", according to Treasury Secretary Scott Bessent.

Although the administration hasn't released a list of all the countries that Trump said on Tuesday were "kissing my ass" and promising to do anything, the US has announced it is in negotiations with South Korea and Japan, among others.

The takeaway: America's trading partners have 90 days to strike some sort of agreement with Trump, and the clock is ticking. But the fact that talks are happening indicates that the president has a good chance of getting something for his efforts.

• What does the tariff pause mean for global trade?

2) Boosting American industry

What Trump said: Jobs and factories will come roaring back into our country…We will supercharge our domestic industrial base.

Trump has said for decades that tariffs are an effective way of rebuilding America's manufacturing base by shielding it from unfair foreign competition. While some factories may be able to increase production in current facilities, more substantive efforts take time. And for business leaders to pull the trigger on "reshoring" their production lines and investing in new US factories, they will want to know that the rules of the game are relatively stable.

The president's on-again, off-again tariff moves over the past week are inherently unstable, however. For the moment, it's difficult to predict where the final tariff levels will land and which industries will receive the greatest protections. It could be auto manufacturers and steel producers today, and high-tech electronics companies tomorrow.

The takeaway: When tariffs are applied and removed seemingly at the president's whim, it's much more likely that companies – both in the US and abroad – will hunker down and wait for the dust to settle before making any big commitments.

3) Facing off with China

What Trump said: I have great respect for President Xi of China, great respect for China, but they were taking tremendous advantage of us.

After Trump's tariff about-face on Wednesday, several White House officials – including Treasury Secretary Bessent - were quick to say that Trump's goal was to drop the hammer on the real villain, China.

"They are the biggest source of the US trade problems," Bessent told reporters, "and indeed they are the problem for the rest of the world.

If Trump wanted a battle of wills with China, testing each side's tolerance for economic and political pain, he got one – even if the president and his aides have hinted that they are looking for an exit ramp.

On Wednesday, Trump said that he blamed past US leaders, not China, for the current trade dispute. The prior day, White House press secretary Karoline Leavitt said the president would be "incredibly gracious" if China reaches out to make a deal.

The takeaway: Even if this showdown is one Trump wants, picking a fight with the second-largest economy in the world, with military power to match, comes at enormous risk. And along the way America may have alienated the allies it needs most in such a confrontation.

• Why Trump is hitting China - and what might happen next

4) Raising revenue

What Trump said: Now it's our turn to prosper, and in so doing, use trillions and trillions of dollars to reduce our taxes and pay down our national debt, and it'll all happen very quickly.

During last year's presidential campaign, Trump regularly touted that his proposed tariffs would bring in vast sums in new revenue, which the US could then use to shrink its budget deficit, fund tax cuts and pay for new government programmes.

A study last year by the nonpartisan Tax Foundation estimated that a 10% universal tariff – which is what Trump has landed on for at least the next 90 days – would generate $2tn in new revenue over the next 10 years.

To put that in context, the tax cuts Congress recently included in its non-binding budget blueprint would cost approximately $5tn over the next 10 years, according to the Bipartisan Policy Center.

The takeaway: Trump wanted more tariff revenue, and if he sticks with his baseline tariffs, plus the additional levies on certain imports and larger ones on China, he's going to get it – at least until Americans switch to more domestic production, when the tariff money gusher could turn to a trickle.

• Is the US making $2bn a day from tariffs?

5) Lower prices for US consumers

What Trump said: Ultimately, more production at home will mean stronger competition and lower prices for consumers. This will be indeed the golden age of America.

Analysts and experts have offered a grab bag other explanations about why Trump made such an aggressive move on trade last week. Was he trying to drive down interest rates, or devalue the US dollar or bring the world to the table for a new, global agreement on trade? The president himself hasn't spoken much about those kinds of elaborate schemes.

One thing he has talked about relentlessly, however, is his desire to lower costs for American consumers - and he has promised that his trade policy will help address this. While energy prices dipped in the week since Trump announced his tariff plan, that may have been a result of fears that the trade wars could trigger a global recession.

The consensus among economists is that new tariffs will drive up consumer prices, as tariffs are tacked on to the price of imports and, eventually, when there is less competition for US-made products. Last year, the Tax Foundation estimated that a 10% universal tariff would increase costs for American households by an average of $1,253 in its first year. Economists also warn that lower-income Americans will be hardest hit.

The takeaway: An increase in prices is an arrow moving in the wrong direction – and it represents an enormous potential liability for both Trump's political standing and his party's future electoral prospects.

A new type of drug for one of the most common kinds of advanced breast cancer is now available on the NHS in England.

Some 3,000 women a year could benefit from capivasertib after a clinical trial showed it can slow progression of the disease, and shrink tumours in a quarter of people.

The drug has been given the green light for NHS funding by England's drug assessment body.

It's one of a range of treatment options available to people whose cancer has spread and is no longer curable, but a cancer charity said breast cancer drugs should be approved more quickly.

Breast cancer is the most common cancer in the UK, with one in seven women affected in their lifetimes and 75% surviving for 10 years or more after diagnosis.

If the cancer returns and spreads to other parts of the body, treatments aim to control it, reduce the symptoms and improve quality of life.

Possible treatments include chemotherapy, radiotherapy and drugs that help to stop the cancer growing - either by blocking hormones, boosting the body's immune system or targeting what makes cancer cells grow.

This new drug capivasertib is a targeted therapy. It works in a new way, blocking the activity of a protein molecule called AKT which drives cancer growth.

Scientists started working on the drug's development 20 years ago and say it's the most effective cancer drug they've seen for advanced cancer.

"It presents a very effective option that can work for a long time - many months, and in some people it can be years," said Prof Nick Turner, lead researcher and professor of medical oncology at the Institute of Cancer Research and The Royal Marsden.

In trials, in 708 women, when combined with hormone therapy, the drug doubled the time the cancer took to grow, from 3.6 months to 7.3 months. It also shrank tumours in 23% of patients.

"It can substantially delay chemotherapy which many women fear because of the side-effects," Prof Turner added.

"Advanced breast cancer is highly treatable and we want kinder, better treatments."

'Four years of extra time'

Linda Kelly, 67, is a keen gardener who keeps active by cycling 60 miles a week. She also does pilates.

Breast cancer has spread to her bones and chest wall.

But she's had "fantastic" results from the new drug capivasertib.

"It does let you have a normal kind of life and you forget you have cancer," she said.

"You feel the drug is working and you can be a lot calmer - it's given me nearly four years of extra time."

Linda and her husband are now planning to travel. She says the drug has given her hope.

"It does make you think about your life, and what you want to do with your life in the future - but at least you feel well enough to make those plans and confident enough as well to fulfil some of those plans."

The drug is suitable for those with certain gene mutations that affect up to half of people with hormone receptor positive secondary breast cancer - the most common type, which grows in the presence of oestrogen.

Professor Peter Johnson, clinical director for cancer at NHS England, said it offered "an additional option" for some whose cancer has progressed despite previous hormone therapy - but it wouldn't be suitable for everyone.

Claire Rowney, chief executive at charity Breast Cancer Now, said she was "delighted" that the drug would offer some people "the hope of more precious time to do what matters most to them".

But she said patients had "faced unnecessary delays in accessing it" after the drug was initially rejected by NICE, and breast cancer drugs should be approved more quickly for those who need them.

"NHS England must now put in place prompt genetic testing to ensure those eligible receive capivasertib without further delay," she said, adding that Scotland should also consider funding the treatment quickly so that patients across the UK would have access.

Long-running Salah saga finally ends

Analysis - The importance of contracts being two years